A real-world observational study presented at the 2026 European Respiratory Society (ERS) Congress [S1], [S2], [S3], [S4] links the use of GLP-1 receptor agonists—particularly semaglutide—to a reduced risk of respiratory exacerbations. The research evaluated UK electronic medical records to compare new users of GLP-1 medications against new users of sulfonylureas [S1], [S2], [S3], [S4]. Findings showed that semaglutide was associated with a 38% to 40% lower risk of asthma attacks and a 20% lower risk of chronic obstructive pulmonary disease (COPD) flare-ups [S1], [S2], [S3], [S4].
Study Design and Respiratory Findings
Described as one of the largest real-world evaluations of GLP-1 receptor agonists in airway disease [S3], [S4], the project analyzed four parallel cohorts, each comprising approximately 20,000 to 22,000 participants [S1], [S2], [S3], [S4]. The overall new-user group included 8,266 individuals taking GLP-1 medications and 20,273 individuals taking sulfonylureas [S3]. Weighted propensity scoring was applied to balance the groups [S3]. The examined GLP-1 drugs included semaglutide (marketed as Ozempic and Wegovy), exenatide, dulaglutide, liraglutide, and lixisenatide [S1], [S2], [S3], [S4].
While semaglutide demonstrated the most pronounced association, other GLP-1 agents also showed varying degrees of association with reduced exacerbations. Exenatide was tied to a 23% reduction and dulaglutide to a 12% reduction in exacerbations, whereas liraglutide and lixisenatide showed no significant effect [S3]. Exacerbations within the study were defined by events requiring a short course of oral steroids, an emergency department visit, hospitalization, or death [S3].
Additionally, the evaluation found that the observed effects were not modified by metabolic phenotype factors such as baseline body mass index, HbA1c, insulin resistance, weight change, or glycemic control [S3]. Study authors noted that because GLP-1 medications possess known anti-inflammatory properties [S1], [S2], [S3], [S4], there may be direct pulmonary mechanisms contributing to these outcomes [S3].
Methodological Limitations and Clinical Cautions
Despite the notable correlations observed in the UK electronic health record data, the study design remains observational, meaning it cannot prove causation between GLP-1 receptor agonist use and reduced respiratory events [S1], [S2], [S3], [S4]. Observational analyses carry inherent limitations regarding unmeasured confounding factors, even after applying weighted propensity scoring to balance the GLP-1 and sulfonylurea cohorts [S3].
Furthermore, the research presented at the European Respiratory Society Congress was not yet peer-reviewed at the time of its presentation [S1], [S2], [S3], [S4]. The exact underlying biological mechanisms connecting these medications to improved airway outcomes remain unproven and require dedicated investigation [S3].
In response to these findings, the study authors emphasized clear clinical boundaries. They cautioned that GLP-1 receptor agonists should not be prescribed specifically for the treatment of asthma or chronic obstructive pulmonary disease outside of current established medical guidelines [S1], [S2], [S3], [S4]. Currently, these pharmaceuticals are officially approved to manage type 2 diabetes and obesity, alongside documented cardiovascular benefits [S2].
Addressing these clinical uncertainties will require further research. Specifically, the authors noted that formal randomized trials are necessary to properly evaluate whether GLP-1 receptor agonists genuinely provide causal therapeutic benefits for patients with chronic respiratory conditions [S1], [S2], [S3], [S4].